#nicotinamide riboside

2 articles

Approach: conceptual metaphor. Palette: bold color field.

A single AA-style cylindrical battery, shown as a real object with a bare metal cap and a plain unlabeled matte sleeve, stands upright on a glossy surface. It is photographed from a low three-quarter angle against a saturated tomato-red seamless backdrop. The battery is half-filled with a translucent amber liquid that visibly rises inside a clear glass cutaway section. A thin ribbon of electric green light (#00e676) wraps around its base like a charging band. Soft large-softbox light comes from the upper left and produces crisp highlights on the metal and a clean, slightly blurred red reflection beneath it. A second, shorter battery sits out of focus behind, nearly drained and empty, to suggest contrast. The mood is energetic, optimistic and precise, with a tactile product-photography look and shallow depth of field.

NR + Pterostilbene Nambah NAD+ Kira‑kira 40–90 % ing Uji Manungsa

BY NOVA CHEN · Oct 16, 2026

Apa kapsul saben dina sing ngandhut nicotinamide riboside lan pterostilbene isa nambah NAD+ ing wong tuwa? Ing uji coba kapisan NRPT (Basis) sing ditindakake ing manungsa, 120 wong umur 60‑80 taun njupuk suplemen iki sajrone wolung minggu. NAD+ ing getih mundhak kira‑kira 40 % kanthi dosis sing disaranake lan 90 % kanthi dosis dobel, lan kenaikan iki tetep stabil nganti pungkasan uji. Ora ana efek samping serius sing dilaporaké.

A bright, minimalist editorial still life on a pale warm-white stone surface, shot from a slightly elevated three-quarter angle in soft natural window light. At center, a small amber glass supplement bottle with a matte cream label, unbranded, sits beside a few loose white capsules. A pair of weathered hands in a light oatmeal linen sleeve, belonging to an older adult, rests gently near the bottle, with a ceramic mug of tea just out of focus. To the right, a clean glass vial and a delicate glass beaker filled with clear liquid catch the light, hinting at laboratory research without any futuristic touch. A small paper notebook with a handwritten simple line graph rising in a gentle curve lies open nearby, along with a sharpened pencil. Scattered at the edges are soft sprigs of dried eucalyptus and a few pale sage-green leaves, adding an organic note. A faint, abstract molecular diagram printed in muted teal ink on a card leans against the bottle, subtle and graphic. The palette is calm and modern: warm ivory, sage green, soft teal, muted amber, and touches of dusty peach. Long, gentle shadows fall across the surface, and the shallow depth of field blurs the background into creamy neutral tones. The composition leaves generous negative space on the left third for headline text. The overall feel is a trendy health and science journal: clean, airy, trustworthy, and quietly sophisticated, with fine film-like grain and true-to-life color. Ultra-detailed, 16:9 landscape.

supplements

1.000 mg Nicotinamide Riboside saben dina nambah NAD+ ing sel getih kira‑kira 60 % ing wong diwasa tuwa, asil uji coba acak

BY DR. SYNAPSE · Oct 15, 2026

Uji coba crossover ing *Nature Communications* taun 2018 nyoba Nicotinamide Riboside (NR) 500 mg kaping loro saben dina (total 1.000 mg) nganti enem minggu marang wong diwasa sehat umur setengah umur nganti pra‑tua. Suplemen iki ditampa kanthi apik lan nambah NAD+ ing sel imun getih kira‑kira 60 % tinimbang plasebo. Peneliti uga nyatet sinyal wiwitan babagan tekanan darah sing luwih murah lan kekakuan arteri, nanging iki mung gagasan kanggo uji coba gedhé, ora bukti manfaat sing pasti. Artikel iki nerangake kenapa NAD+ dipikir turun bareng umur, apa sing ditindakake studi, lan apa sing ora bisa diceritakake babagan hasil penyakit utawa umur panjang.

#nicotinamide riboside

NR + Pterostilbene Nambah NAD+ Kira‑kira 40–90 % ing Uji Manungsa

1.000 mg Nicotinamide Riboside saben dina nambah NAD+ ing sel getih kira‑kira 60 % ing wong diwasa tuwa, asil uji coba acak

NR + Pterostilbene Nambah NAD+ Kira‑kira 40–90 % ing Uji Manungsa

1.000 mg Nicotinamide Riboside saben dina nambah NAD+ ing sel getih kira‑kira 60 % ing wong diwasa tuwa, asil uji coba acak